Method for the creation of a database for initial assessment of the effectiveness of active agents in tumor therapy
AssigneeFLACOD GmbH
InventorChristof GRANZOW
Life of this patent
Estimating the term…
Abstract
The method comprises the steps wherein the tumour cells from a tumor tissue sample previously taken from a particular patient are incubated ex vivo with the active agent concerned and the IC50 value thereof for these cells is determined; wherein the same patient is treated with this active agent in accordance with evidence-based therapy rules; wherein the therapy outcome is documented and classified; and wherein the documentation and/or classification of the therapy outcome obtained is assigned to the IC50 value determined ex vivo.
Claims18
A method for creating a database for the initial assessment (pre-assessment) of the efficacy of a cytostatic active substance (cytostatic drug) in the chemotherapeutic treatment of a tumor, especially a malignant tumor, of a particular patient on the basis of ex vivo determination of the IC50 value of the active substance for the tumor cells of a previously obtained tumor tissue sample from the same patient, comprising the following measures:
- the tumor cells (especially the malignant cells) of the previously obtained tumor tissue sample (or malignant tissue sample) of the patient are incubated ex vivo with the active substance concerned,
- the IC50 value of this active substance in these cells is determined,
- the ex vivo determined IC50-value is assigned to the documentation and/or classification of the therapy outcome obtained with the same patient after treatment according to applicable evidence based therapy rules with the same active substance.
(canceled)
A method for the initial assessment (pre-assessment) of the efficacy of an active (cytostatic) substance (drug) in the therapeutic treatment of a tumor, particularly a malignant tumor, of a specific (certain) current patient, wherein
- the tumor cells of a previously obtained tumor tissue sample from the patient are incubated ex vivo with the active substance concerned and the IC50 value of this active substance is determined in these cells,
- the determined IC50 value is compared with previously determined reference IC50 values of the same active substance for tumor cells of the same tumor entity, wherein each reference IC50 value is assigned a therapy outcome obtained from that patient whose tumor cells had been used for obtaining said reference IC50 value after a treatment with the active substance according to applicable evidence-based therapy rules,
- and a match between the IC50 value of the tumor cells of the current patient and a reference IC50 value is considered to be an indication that the therapy outcome assigned to this reference value will also occur in the case of treatment of the current patient.
A method of selecting a platinum derivative/platinum analogoue/platinum compound as active substance or part of a combination of active substances in a chemotherapy predictive of partial response or zero growth of a tumor, particularly a malignant tumor, in a specific/certain patient, comprising:
- incubating the tumor cells (especially the malignant cells) of a previously obtained tumor tissue sample of the patient ex vivo with the platinum derivative/platinum analogoue/platinum compound and determining the IC50-value of this active substance in these patient's cells,
- comparing the obtained ex vivo determined IC50-value with previously determined reference IC50-values of the same active substance with tumor cells of the same tumor entity, wherein each of these reference IC50-values is assigned to a therapy outcome obtained from that patient whose tumor cells had been used for obtaining said reference IC50-value after chemotherapeutic treatment with the active substance according to applicable evidence-based therapy rules,
- and wherein a match with a reference IC50-value is an indication that the therapy outcome assigned to this reference IC50-value will also occur in the case of treatment of said specific/certain patient's lung cancer (bronchial carcinoma) with a platinum derivative/platinum analogoue/platinum compound as active substance or part of a combination of active substances.
Dependencies are inferred from the claim text.